• Local and Systemic Therapy of Recurrent Ependymoma in Children and Adolescents: Short- and Long-term Results of the E-HIT-REZ 2005 Study

    • The treatment of ependymoma has traditional been limited to surgical resection in isolation as radiation and chemotherapy display limited efficacy in improving progression-free and overall survival.
    • The goal of this study was to assess the German multi-center E-HIT-REZ-2005 study for efficacy of radiation and chemotherapy in adolescent and pediatric ependymoma patients at 1st recurrence.
    • The study enrolled patient from 2006 – 2013 and enrolled a total of 53 patients with a median age of 6.9 years (range: 4-14 years) representing 45% of the patient population in Germany during this time period treated for ependymoma at 1st recurrence.
    • Median overall survival in the enrolled patient population was 36 months with a 5-year overall survival of 37% +-66%.
    • 21 patients received temozolomide prior to re-resection and 18 (85.7%) displayed progression at a median of 1 month after treatment onset.
    • 21 patients received radiation prior to re-resection and median PFS was similar between the radiated group at 21 months compared to the non-irradiated group at 19 months and median OS was equivalent between groups at 36 months.
    • 37 patients in the study that received re-resection at the time of 1st Patients with GTR/NTR displayed a significantly increased PFS at 25.9 months (CI:15.0-36.6) and OS at 71 months (CI:12.7-129.3) as compared to patients with subtotal resection with PFS at 9.2 months (CI: 7.2-23) and OS at 20.6 months (CI:3.8-37.4).
    • Multivariate Cox regression analysis revealed that GTR/NTR displayed the largest reduction in risk of death.
    • While the patient cohort is relatively small, this multi-center study further validates the limited efficacy of chemotherapy and radiation in patients with ependymoma and the importance of maximum safe surgical resection.


    New England Journal of Medicine

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site here. Privacy Policy